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Abstract
It is becoming increasingly clear that microbiota which inhabit our body influence cancer 
predisposition and etiology. In addition to pathogens with oncogenic properties, our commensal 
and symbiotic microbiota have tumor-suppressive properties. Our diet and other environmental 
factors can modulate the abundance of certain members of microbial communities within our 
gastrointestinal tract and at other anatomical sites. Furthermore, some dietary factors are 
metabolized by commensal/symbiotic gut microbiota into bioactive food components believed to 
prevent cancer. For example, dietary fiber undergoes bacterial fermentation in the colon to yield 
butyrate, which is a short-chain fatty acid and histone deacetylase (HDAC) inhibitor that 
suppresses the viability and growth of colorectal cancer cell lines. A recent study utilizing 
gnotobiotic mouse models demonstrates that fiber can protect against colorectal tumorigenesis in a 
microbiota- and butyrate-dependent manner that involves the Warburg effect. This and other 
examples suggest that some of the inter-individual variation observed in epidemiology and 
intervention studies that have investigated associations between diet and cancer risk might be 
explained by differences in microbiota among the participants. Data from basic research studies 
also support the idea that probiotics and prebiotics could be plausible chemoprevention strategies 
that may be utilized to a greater extent in the future.
Introduction
Cancer is a leading cause of death that is associated with tremendous social and economic 
burdens. According to the National Cancer Institute (NCI), healthcare costs associated with 
the diagnosis and treatment of cancer in the United States currently exceed $125 billion per 
year (1). This figure is projected to rise because of healthcare inflation and demographics- 
the obesity epidemic and the aging of the United States population will undoubtedly increase 
the number of cases. Although targeted therapies such as imatinib (Gleevac) and 
trastuzumab (Herceptin) are efficacious at treating certain cancer subtypes, the vast majority 
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of cancer cases still rely on conventional anticancer chemotherapeutics with varying degrees 
of efficacy and adverse effects. Therefore, a major goal is cancer prevention. It is estimated 
that 25–30% of cancer cases are due to tobacco use, 15–20% are due to infections, and 30–
35% of cancer cases are preventable via a healthy diet, physical activity, and maintaining a 
healthy body weight (2, 3). There is much interest in understanding the underlying 
mechanisms of cancer preventive effects, and it is becoming increasingly clear that the 
commensal microbiota that inhabit our body can inhibit pathogens from mounting infections 
and that they can also metabolize whole foods into bioactive food components that promote 
intestinal homeostasis and may prevent cancer. This review will discuss how microbiota that 
inhabit our body are detected and quantified followed by a discussion of cancer-prevention 
mechanisms and the prospect for probiotic and prebiotic strategies of cancer prevention.
The human microbiome
The human body harbors ≥1014 microbial cells, which is estimated to be ~10-fold greater 
than all of our somatic and germ cells combined (4). They are comprised of Bacteria, 
Archaea, Eukaryotes (such as yeast and other fungi), and viruses (including bacteriophage). 
Our microbiota and their collective genomes, which are referred to as the microbiome and 
harbor ~100-fold more genes than the human genome, are being characterized by 
metagenomics approaches that combine next-generation sequencing with the computational 
analysis of targeted (16S rRNA hypervariable regions) and random (whole-genome shotgun) 
DNA sequence reads (5–7) (Figure 1). Based on these studies, we know that the 
composition of microbial communities varies across different anatomical sites (8, 9). 
Furthermore, these communities are dynamic rather than static because the composition of 
microbiota at any given site within an individual can change in response to diet and other 
lifestyle or environmental factors (10–12). We also know that the vast majority of these 
microbes are bacteria that reside within the lumen of our gastrointestinal (GI) tract. The 
commensal and symbiotic bacteria that live within our gut are protected from predators such 
as nematode roundworms, and they also benefit from a consistent supply of nutrients 
provided by our carbohydrate-rich diets (Figure 2). In return, many of the symbiotic bacteria 
digest glycans into disaccharides and monosaccharides for energy utilization by the human 
host as well as microbiota (Figure 2). To carry out this function, the gut microbiome is 
highly enriched for genes involved in carbohydrate metabolism including ≥115 families of 
glycoside hydrolases and ≥21 families of polysaccharide lyases (13, 14). In contrast, the 
human genome has relatively few genes that encode carbohydrate-metabolizing enzymes, 
presumably because mammals (and their genomes) co-evolved with gut microbiota (and the 
gut microbiome). As a result of this symbiotic relationship, gut microbiota are believed to 
improve our ability to absorb nutrients and extract calories from our diets (15, 16). Gut 
microbiota also produce essential vitamins such as vitamins K and B12 (17). Consequently, 
germfree mice, which are maintained devoid of all microbiota in gnotobiotic facilities 
(Figure 3), must be provided a diet that is fortified with additional vitamins other than those 
obtained through diet alone.
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The microbiome and cancer
Metagenomic sequencing projects have compared the composition of microbial 
communities in human disease cases to controls (Figure 1), and these association studies 
have implicated our microbiota in the prevention of many diseases including various types 
of cancer (18, 19). Normal diverse microbial communities can protect against cancer by 
multiple mechanisms. They can have an indirect effect by competing with pathogens for 
attachment sites, which limit pathogen abundance and prevent infections that drive 
carcinogenesis (Figure 4). The oncogenicity of certain pathogens such as human 
papillomavirus (HPV) and Helicobacter pylori is well established, but recent microbiome 
studies suggest commensals and opportunistic pathogens can also be involved and that 
infections associated with cancer might be more common than the current estimate of 15–
20%. For example, colorectal tumors are enriched for Fusobacterium nucleatum compared 
to normal colonic tissue (20–22). This bacterium was previously linked to periodontitis and 
appendicitis but not cancer. However, this association with cancer is not surprising because 
Fusobacterium nucleatum stimulates inflammation and can protect tumors from immune 
attack (23, 24). F. nucleatum also produces hydrogen sulfide in response to red meat 
consumption, which can induce DNA damage and genomic instability within in the colonic 
epithelium or developing tumors (25, 26). This increases colorectal cancer risk and 
progression, especially for individuals with mutations or perturbations in the DNA-damage 
response (e.g., ATR and ATM) in their germline or adenomas, respectively. Red meat 
consumption also increases cholesterol, which the liver uses to produce primary bile acids 
such as cholic acid that are conjugated to either glycine or taurine and undergo enterohepatic 
circulation. Approximately 5% of primary bile acids escape the enterohepatic circulation 
and reach the colon where specific bacteria deconjugate them (via bile salt hydrolases) and 
convert them into secondary bile acids (via dehydrogenation or dehydroxylation). At least 
one of these secondary bile acids, deoxycholic acid, causes DNA damage via the production 
of free radicals and has been implicated in liver, esophageal, and colorectal cancers (27, 28). 
These are prime examples of how our diet and microbiota can conspire to increase cancer 
risk.
The mucosa of colorectal cancer cases is enriched for Escherichia coli harboring a pks 
(polyketide synthase) pathogenicity island, which consists of a cluster of genes encoding 
enzymes that produce a genotoxic protein, collibactin, that can induce DNA damage in the 
host colonic epithelium (29–31). To demonstrate the importance of this pathogenicity island, 
Il10−/− mice were monoassociated with isogenic E. coli strains either containing or lacking 
(via a targeted deletion) pks in a gnotobiotic facility, and +pks increased the AOM 
(azoxymethane, a pro-carcinogen)-induced colorectal tumor burden without exacerbating 
inflammation (29). The mucosa of colorectal cancer cases is also enriched for 
enterotoxigenic Bacteroides fragilis, which corresponds to a subset of B. fragilis strains that 
contain a pathogenicity island encoding a metalloproteinase (32–36). The bacterial-encoded 
metalloproteinase is believed to compromise the barrier function of the colonic epithelium, 
which exposes immune cells in the underlying lamina propria to luminal bacteria and 
bacterial gene products including lipopolysaccharide (LPS) and flagellin (Figure 4). This 
breach and exposure, in turn, leads to immune cell activation and inflammation, which is an 
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emerging hallmark of cancer in general and colorectal cancer in particular (37, 38). It is 
likely that the B. fragilis toxin has additional oncogenic functions. It can cleave E-cadherin 
and activate the Wnt/β-catenin pathway, and human-encoded metalloproteinases play an 
important role in tumor invasion and metastasis. Future studies will likely link additional 
microbiota to cancer, especially in cases where any one microbe has a subtle or modest 
effect while the combined effect of multiple microbes in aggregate is more robust. Microbes 
that have modest contributions may be dependent on genetic background of the host, which 
would result in greater inter-individual variation, and will be more difficult to detect than 
dominant pathogens capable of driving “one microbe-one disease” neoplasms such as HPV 
for cervical cancer and H. pylori for gastric cancer. It is also possible that microbiome 
studies often overlook microbes that participate in early stages of tumorigenesis that are not 
involved in the later stages, especially if the growth or survival of these microbiota are 
selected against by the later-stage tumor microenvironment (e.g., low pH due to lactic acid 
because of the Warburg effect). Diet is known to influence the composition of our gut 
microbiota (10–12). Therefore, from a chemoprevention standpoint, a well-balanced diet can 
help maintain a “normal”, albeit undefined, microbiome associated with good health and 
prevent an imbalance of a microbial community associated with diminished diversity, 
pathogenic infections, and increased cancer risk (referred to as dysbiosis).
Our commensal and symbiotic bacteria also diminish cancer risk in more direct ways than 
by inhibiting pathogens. This more direct route primarily involves their ability to metabolize 
dietary factors into bioactive food components, which can have cell-autonomous effects on 
the tumor or cell-of-origin as well as non-cell-autonomous effects targeting immune cells 
and other stromal cells in the tumor microenvironment (Figure 4). Our gut microbiota can be 
thought of as a second liver because of their prodigious metabolic capacity, which is not 
limited to calorie extraction, and the identification of microbial-derived metabolites that 
participate in disease prevention is a very active area of research (39). For this reason, the 
current trend is to move beyond basic microbiome studies, as outlined in Figure 1, and 
evaluate the effect of diet and other environmental factors on microbial abundance 
(metagenomics) plus microbial gene expression (metatranscriptomics and metaproteomics) 
and metabolite production (metabolomics). The next three sections focus on dietary fiber 
and colorectal cancer as an example of how gut microbiota can process bioactive food 
components into a metabolite relevant to chemoprevention.
Dietary fiber and colorectal cancer prevention
One of the most extensively studied dietary factors in chemoprevention has been fiber, 
which is defined as “the edible part of plants or their extracts, or analogous carbohydrates, 
that are resistant to digestion and absorption in the small intestine, but are utilized after 
partial or complete fermentation in the large intestine by resident microbiota” (40). Fiber 
includes polysaccharides (e.g., resistant starch, cellulose, hemicellulose, pectins, and gums), 
oligosaccharides, and lignins. As human populations have shifted away from traditional, 
high-fiber diets towards processed foods containing refined sugars, colorectal cancer 
incidence has increased markedly. Colorectal cancer is now the third most diagnosed cancer 
in both men and women in the United States, and it is also the third most deadly (41). This 
trend of increasing colorectal cancer incidence is most evident in China and developing 
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countries that have rapidly adopted western diets in recent years (42). The correlation 
between decreased fiber consumption and increased colorectal incidence is also pronounced 
in developing countries because colonoscopies are performed on a limited basis. In contrast, 
widespread screening and removal of pre-cancerous adenomas in the United States has 
coincided with a recent decline in colorectal cancer incidence.
Yet the link between fiber consumption and prevention of colorectal adenomas and 
adenocarcinomas has been inconclusive, partly because ecologic studies, as described above 
and which provided the basis for Burkitt’s original proposal that fiber is protective (43), are 
not rigorous. More rigorous prospective-cohort studies have been performed but have given 
rise to conflicting results (44–49), which has made this a controversial topic. However, it 
should be noted that these epidemiologic studies and mouse models of colorectal cancer 
have not controlled the composition of gut microbiota, which varies between individuals and 
is known to ferment fiber into short-chain fatty acids such as butyrate. Butyrate is highly 
abundant (present at mM levels in the lumen of the colon) and noteworthy because it has 
energetic and epigenetic functions in colonocytes and tumor-suppressive properties in 
colorectal cancer cell lines (50).
Dietary fiber-microbiota-butyrate axis
Recent studies have demonstrated that fiber consumption alters the composition of our gut 
microbiome to a greater extent than other dietary factors and increases the number of 
butyrate-producing bacteria (10–12). Furthermore, ≥5 microbiome studies have reported a 
significant decrease in butyrate-producing bacteria in human colorectal cancer cases 
compared to controls. However, one limitation of microbiome studies is that it is difficult to 
know whether a particular microbiome change is a cause or a consequence of the disease. 
For this reason, it is important to study mouse models maintained in gnotobiotic facilities 
where the microbiota can be manipulated (Figure 3). In addition to maintaining these mice 
in a germfree state, they can be colonized with one or more defined bacteria, which allows 
bacterial function in mammalian health and disease to be interrogated, as exemplified by the 
E. coli pks pathogenicity island study described above. To investigate dietary fiber and 
butyrate in a highly controlled manner, a mouse model of colorectal cancer was 
polyassociated with several bacteria in a gnotobiotic facility and provided control or high-
fiber diets that were otherwise essentially identical and isocaloric (51, 52). The high-fiber 
diet was provided from weaning (i.e., prior to tumor initiation) until the time of sacrifice and 
had a protective effect in mice colonized with a wild-type butyrate-producing bacterium but 
not in mice lacking a butyrate producer (Figure 5). The same mice colonized with a mutant 
strain of the butyrate-producing bacterium, which harbors a small deletion in the butyrate 
synthesis operon and produces diminished levels of butyrate, had an attenuated protective 
effect with an intermediate tumor burden (Figure 5). Furthermore, mice that completely 
lacked butyrate-producing bacteria but were provided a diet fortified with butyrate had a 
lower tumor burden than any of the other treatment groups(Figure 5). This is arguably the 
most convincing evidence that butyrate is a causal factor because it demonstrates that the 
fiber-microbiota chemopreventive effect can be recapitulated by exogenous butyrate.
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This study also explored the molecular mechanism of how butyrate functions as a microbial-
derived tumor-suppressive metabolite (51). Unlike most cell types in the body, which utilize 
glucose as their primary energy source, normal colonocytes rely on butyrate for ~60–70% of 
their energy (53–55) (Figure 6). As a fatty acid, butyrate undergoes β-oxidation in the 
mitochondria, and this supports energy homeostasis necessary for the rapid cell proliferation 
of the colonic epithelium, which is renewed every ~7 days (it and the small intestinal 
epithelium arguably turn over faster than any other tissue in the body). In contrast, colorectal 
tumor cells (and tumor cells in general) undergo the Warburg effect and switch to glucose 
utilization and aerobic glycolysis (56) (Figure 7). As a result of this metabolic shift, butyrate 
is not metabolized in the mitochondria of tumor cells to the same extent and accumulates in 
the nucleus where it functions as a histone deacetylase (HDAC) inhibitor to epigenetically 
regulate gene expression (51, 57) (Figure 6). In support of this model, butyrate (detected by 
LC-MS) and global histone acetylation levels (detected by immunohistochemistry and 
western blots) were elevated in tumors from mice that were colonized with the wild-type 
butyrate producer and provided a high-fiber diet, and this correlated with a lower tumor 
burden (Figure 5). Butyrate is a well-established HDAC inhibitor (58, 59), and butyrate 
target genes in tumors from mice provided a high-fiber diet included Fas and p21, which 
promote apoptosis and inhibit cell-cycle progression, respectively. This finding is 
compatible with the diminished tumor burden in these mice and the idea that butyrate is a 
tumor-suppressive metabolite.
However, the chemoprotective mechanism(s) could be more complicated than described 
above. Insoluble fibers such as cellulose are not fermented by gut microbiota and speed 
colonic transit. Decreased transit time is believed to be chemoprotective because it 
diminishes the exposure of colonocytes to ingested carcinogens such as heterocyclic amines 
from charred meats. Soluble fibers are fermented into short-chain fatty acids other than 
butyrate, such as acetate and propionate, and these or other metabolites could also contribute 
to chemoprevention. Finally, butyrate is a pleiotropic molecule that may function by 
additional mechanisms. In addition to functioning as an HDAC inhibitor, it can signal 
through certain G protein coupled receptors (60, 61). Butyrate could diminish tumorigenesis 
by attenuating inflammation. Butyrate enemas strongly ameliorate colonic inflammation 
associated with inflammatory bowel diseases (IBD) such as colitis and Crohn’s disease in 
both rodent models and human patients (59). This is noteworthy because colitis patients 
have up to a 10-fold increased risk of colorectal cancer (38, 62), which is consistent with the 
link between inflammation and cancer (37). Several recent studies demonstrate that butyrate 
activates FoxP3 expression in CD4+ T cells and dendritic cells to induce the differentiation 
and expansion of immunosuppressive regulatory T (Treg) cells (63–66). Another recent 
study demonstrates that butyrate downregulates the production of pro-inflammatory 
cytokines by intestinal macrophages (67). It will need to be investigated whether these anti-
inflammatory events contribute to fiber-mediated chemoprevention.
Translational potential of the dietary fiber-microbiota-butyrate axis
The idea that butyrate is a tumor-suppressive metabolite is consistent with many published 
studies which have observed that butyrate inhibits the proliferation of colorectal cancer cell 
lines while stimulating their apoptosis and/or differentiation (59, 68). The gnotobiotic mouse 
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experiments described above are valuable because they move beyond “factor dump” 
experiments where relatively high doses of butyrate are added to colorectal cancer cell lines 
in vitro. They demonstrate that dietary fiber and gut microbiota can modulate butyrate levels 
in the colonic lumen, and that this, in turn, can inhibit colorectal tumorigenesis in vivo 
where the colonic crypt architecture is intact and functions in the presence of stromal cells. 
These findings suggest that probiotics (butyrate-producing bacteria in this particular case) 
and/or prebiotics (soluble or “fermentable” fiber in this particular case) can be used to 
increase the levels of an endogenous HDAC inhibitor and diminish tumororigenesis. Unlike 
synthetic HDAC inhibitors, which are delivered systemically as chemotherapeutic agents for 
certain cancers, the probiotic/prebiotic approach should not have adverse effects for a couple 
of reasons (Figure 8). First, the bioavailability of butyrate is primarily restricted to the colon, 
which minimizes the chance of collateral damage in other tissues. Second, because butyrate 
is a naturally occurring fatty acid, it targets tumors cells in the colonic crypt. It is readily 
metabolized by normal colonocytes, whereas it accumulates as an HDAC inhibitor in tumor 
cells due to the Warburg effect.
It should be noted that the gnotobiotic mouse experimental design was reductionist in order 
to demonstrate that butyrate is a causal factor in chemoprevention. The mice were 
polyassociated with only several species of bacteria, which does not accurately model the 
complex microbiota that exist within the human GI tract. The semi-purified diets provided to 
the mice are not representative of our more varied diets that include different sources of 
fiber as well as higher levels of sugar, fat, and red meat, which may exacerbate cancer risk 
and could possibly mask a beneficial fiber effect. Additionally, the mice were provided a 
high-fiber diet at weaning prior to tumor initiation (via azoxymethane [AOM] injection), and 
it is not clear whether fiber would still be protective if provided after the onset of 
tumorigenesis. Nevertheless, despite these caveats, human adenocarcinomas were shown to 
have higher levels of butyrate and histone acetylation than normal colonic samples (51). 
This finding suggests that the gnotobiotic mouse data may be relevant to human cancer 
prevention. Based on this knowledge, it would be interesting to revisit prospective-cohort 
studies that have investigated whether there is a link between fiber consumption and 
colorectal cancer but combine them with microbiome studies. The hypothesis would be that 
if microbiome differences among the participants were taken into account, then it would be 
possible to discriminate between those individuals who respond to the putative 
chemoprotective effect of fiber and non-responders. This would resolve some of the 
conflicting results from previous human studies and possibly confirm butyrate as an 
important molecule in human chemoprevention.
Other bacterial metabolites and cancers
Although the vast majority of our microbiota reside in our gut, they can influence diseases 
beyond our GI tract, such as cardiovascular disease and autism, and this applies to cancer. 
Many gut microbe-derived metabolites have a much broader bioavailability than butyrate, 
and the following paragraphs in this section provide some examples relevant to cancer 
prevention. It should also be noted that bacterial densities are relatively high in close 
proximity to the mucous membranes of other tissues such as the lung and urogenital tract 
epithelia. This physical relationship suggests that local microbial communities will also 
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influence the initiation and progression of carcinomas at these sites. It is also possible that 
microbiota will influence leukemias/lymphomas to a greater extent than other cancers 
because our hematopoietic lineages play a key role in the inflammatory response to 
microbes and microbial products.
Dietary polyphenols, which include flavonoids (e.g., quercetin and kaempferol), phenolic 
acids, anthrocyanins, and lignins present in tea, wine, fruits, nuts, and vegetables, have 
received extensive attention because of their chemoprotective effects in mouse models and 
human epidemiology studies. Resveratrol has probably received the most attention because 
it is a caloric-restriction mimetic that is pleiotropic and benefits health in multiple ways. 
However, it is not the best example for being metabolized by gut microbiota. Although gut 
microbiota can convert it to trans-resveratrol metabolites such as dihydroresveratrol, there 
are considerable inter-individual differences and the functional relevance of these 
derivatives is poorly understood (69). In contrast, ellagic acid is a polyphenol present in 
certain berries and nuts that is an anti-oxidant with cancer-preventive properties. Ellagic acid 
is metabolized by colonic microbiota into urolithins that have pro-estrogenic and anti-
estrogenic activities in a context-dependent manner (70) (Table 1). Urolithins can also 
downregulate COX-2 to lower prostaglandin production and inflammation so the anti-cancer 
effects apparently involve multiple pathways (71). Another polyphenol is daidzein, which is 
a soy-based isoflavone metabolized by gut microbiota into equol (72) (Table 1). Equol can 
be detected in only 30–40% of individuals, and, although the reason for this is not 
understood, it could be due, in part, to the relative abundance of specific bacteria (73, 74). 
The ability to produce equol is positively correlated with sulfate-reducing bacteria and 
negatively correlated with Clostridium coccoides and Eubacterium rectale (75). Some 
epidemiologic studies have reported correlations between equol or equol-producing bacteria 
and diminished breast cancer risk in women and diminished prostate cancer risk in men. 
However, these correlations have been observed in Asian populations but not European 
populations (76). It is not clear whether these ethnic disparities are due to differences in 
genetics, microbiota, or diet (e.g., soy consumption), and more work will be required to 
strengthen the link between equol and cancer prevention. Generally speaking, based on 
situations like this, it would be advantageous to combine epidemiology studies with GWAS 
(genome-wide association studies) or exome sequencing as well as microbiome studies. This 
kind of integrated approach might allow a combination of factors to be identified that have a 
significant and reproducible effect regarding diet and chemoprevention. In addition, it would 
be cost effective and useful to assess relatively short-term probiotic and prebiotic regimens 
by performing metabolomics or analyzing cancer-related biomarkers as surrogates and then 
use this information to direct more expensive, longer-term epidemiology studies or 
intervention trials.
Cruciferous vegetables such as broccoli and cabbage contain high levels of glucosinolates. 
When these vegetables are uncooked and either chopped or chewed, plant-derived 
myrosinases convert the glucosinolates to isothiocyanates (ITC) such as sulforaphane 
(which is an HDAC inhibitor like butyrate) that have anti-carcinogenic properties in cell 
lines and mouse models and might diminish human cancer risk (particularly for lung, breast, 
prostate, colorectal, and prostate although the epidemiology results are mixed). However, 
cruciferous vegetables are usually cooked. Although this denatures the plant-derived 
Bultman Page 8
Semin Oncol. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
myrosinases, bacteria-derived thioglucosidases can convert glucosinolates into ITC in the 
gut to exert their beneficial effects (74) (Table 1).
Linoleic acid is an omega-6 polyunsaturated fatty acid (PUFA) that is a constituent of 
vegetable oils. Because linoleic acid is a precursor of arachadonic acid, which gives rise to 
prostaglandins and inflammation, high intake of vegetable oils can alter the omega-6 to 
omega-3 ratio and be deleterious. However, certain gut microbiota, including strains of 
Lactobacilli and Bifidobacteria used in probiotics, can conjugate linoleic acid (73). Not only 
does this bacterial conjugation diminish linoleic acid levels, but some conjugated linoleic 
acid isomers are reported to have anti-inflammatory and anti-carcinogenic properties (Table 
1).
Probiotics, prebiotics, and the growing functional food/nutraceutical 
industry
The previous section provided some examples of how our gut microbiota influence dietary 
components to potentially prevent cancer (summarized in Table 1), but the reverse is also 
true. In fact, many more food components are known to influence the composition of our gut 
microbiota. Undoubtedly, many more will be discovered and some diet-induced changes in 
microbiota are likely to benefit human health in various ways, including preventing cancer. 
Of course, there are the prebiotics, which have been referred to in above sections and are 
defined as indigestible food ingredients that selectively stimulate the growth and/or activity 
of certain gut microbiota that confer a health benefit. A number of prebiotics have been 
implicated in cancer prevention including various sources of dietary fiber such as inulin that 
promote the growth of Bifidobacteria (73).
A more direct microbial intervention involves probiotics, which have also been referred to in 
previous sections and correspond to live microorganisms present in foods or dietary 
supplements that confer a health benefit. Although there is not much evidence for cancer 
prevention, probiotic bacteria have been implicated in a number of other health outcomes. 
Lactobacilli in yogurt is arguably the best-known example, but Streptococci and 
Bifidobacteria in cheeses and other foods and drinks are also common. One benefit of 
Lactobacilli in yogurt is improved digestion of dairy products in individuals who are lactose 
intolerant. This allows some people to increase their intake of calcium and is noteworthy 
because the prevalence of lactose intolerance ranges from 5–15% in northern European 
countries and the United States to >50% in African and Asian countries (77). The beneficial 
effect is due to live bacteria, which provide β galactosidase (lactase) activity, because heated 
or pasteurized yogurt is not effective (77). Microbiome studies suggest that yogurt must be 
consumed on a regular basis (probably daily) to maintain elevated levels of Lactobacilli 
(12). Probiotics can be improved by supplementing foods with bacteria engineered either to 
have stronger beneficial effects or to more stably colonize the human GI tract. For example, 
although Lactobacillus acidophilus is a beneficial bacteria commonly utilized as a probiotic, 
a glycolipid present in the cell wall, lipoteichoic acid, can potentially have adverse effects 
by stimulating inflammation via Toll-like receptor 2 and cytokine production (78, 79). To 
address this concern, a strain of Lactobacillus acidophilus was engineered with a deletion in 
the phosphoglycerol transferase gene that is unable to synthesize lipoteichoic acid, and oral 
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administration of this bacterium to ApcΔfloxed mice resulted in the regression of already 
established colonic polyps (80). Strains of Lactobacillus casei and Lactococcus lactis have 
also been engineered to produce a protein called elafin that diminished inflammation in a 
mouse model of colitis (81). When these bacteria were added to inflamed epithelial cells 
from human colitis patients ex vivo, they attenuated cytokine production and cell 
permeability. A final example is a strain of Lactobacillus gasseri engineered to overexpress 
the antioxidant superoxide dismutase that decreased colitis in IL-10 knockout mice (82). 
Delivery of these Lactobacilli as improved probiotics would be considered functional foods 
or nutraceuticals, which usually do not involve microbes and include vitamin-fortified foods 
such as golden rice (a genetically-modified crop engineered to contain beta carotene) and 
various foods fortified with omega-3 PUFAs (e.g., cereal, pork, eggs). The functional food/
nutraceutical market is growing rapidly; in the United States, it has increased by 31% since 
2006 to a value of $7.5 billion (and $24 billion globally). Although functional foods and 
nutraceuticals will likely prove useful for many individuals, many unsubstantiated claims 
are made by this industry so products must be evaluated on a case-by-case basis. This is 
particularly true for dietary supplements because they do not require Food and Drug 
Administration (FDA) approval.
Probiotic and prebiotic strategies will prove more efficacious than antibiotic treatments for 
the purpose of chemoprevention. Although antibiotics have been shown to decrease the 
tumor burden of some mouse models (most likely via diminished inflammation), they are 
not good candidates for chemoprevention or chemotherapeutic adjuvants in the clinic. Not 
only does the overuse of antibiotics make the problem of antibiotic-resistant bacterial strains 
even worse, but it kills many commensal/symbiotic bacteria including some that likely 
promote homeostasis and protect against carcinogenesis. Furthermore, not all bacteria return 
to normal levels following antibiotic treatment (12). It has been proposed that our pervasive 
antibiotics usage is altering our microbiota and contributing to the increased incidence of 
obesity, IBD, allergies, and asthma (83), and this might also apply to certain cancers. In fact, 
as H. pylori has been erradicated to a large extent, gastric cancer has decreased but 
esophageal cancer has became more common. One possibility is that H. pylori can alter 
stomach pH and acid reflux in a manner that protects against Barrett’s esophagus and 
esophageal cancer (83). Therefore, instead of using antibiotics to kill bacteria 
indiscriminately, it would be better to take steps that maintain or restore a beneficial 
microbial composition. This is the basis for fecal microbiota transplantations (which can be 
considered a probiotic treatment) that are very effective for the treatment of diarrhea in 
people with severe Clostridium difficile infections, which usually arise because antibiotics 
eliminated commensal bacteria that are capable of displacing or suppressing C. difficile. 
Although the notion that global transplantation of microbiota might function as a cancer 
preventive intervention is not yet a reality, the application of such bacteriotherapy to the 
prevention setting holds promise for the future.
Future directions
We have not yet developed culture conditions that support the growth of most microbes that 
inhabit the human body, particularly anaerobic bacteria that reside deep within our GI tract. 
This limitation has not prevented us from using metagenomics to characterize microbial 
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populations and to identify microbiome differences between individuals with certain 
diseases including cancer compared to controls. It is important that microbiome studies 
continue and that they become integrated with epidemiology studies (especially with respect 
to diet), GWAS, and metabolomics. However, it will become increasingly important that we 
are able to culture specific bacteria so they can be analyzed in gnotobiotic mouse models. 
This approach will allow us to move from correlation to causation and will provide insight 
into molecular mechanisms, which may lead to improved probiotic/prebiotic strategies of 
disease prevention.
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Figure 1. 
A flowchart showing basic steps of a microbiome study. See cited references for details.
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Figure 2. 
A symbiotic relationship exists between humans and our gut microbiota regarding energy 
homeostasis. Humans provide gut bacteria with a protected environment and carbohydrates. 
The gut microbiome is enriched for genes that encode enzymes such as glycoside hydrolases 
(GH) and polysaccharide lyases (PL) that catabolize complex carbohydrates into simpler 
sugars that are utilized by both the gut microbiota and us as their human hosts.
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Figure 3. 
Gnotobiotic mouse models of cancer are crucial for probing the importance of microbiota in 
chemoprevention. Image of a gnotobiotic mouse facility. Mice are maintained in isolators 
(n=6 are pictured) where the air is filtered with a specialized HEPA filtration system (white 
cylinders). Everything that enters the isolators (e.g., cages, bedding, food, water) is 
autoclaved in advance (usually inside of metal canisters) and enters through an airlock 
system (circular structures) after the exterior surface is sprayed with antiseptic. The mice are 
handled using a glovebox apparatus (not pictured, located on other side of isolators). The 
mice can be maintained germfree (i.e., devoid of all microbiota) or they can be colonized 
with one or more specific microbiota introduced by gavage. The mice can be “humanized” 
by colonizing them with human-derived microbiota, including from disease cases versus 
controls, to interrogate the function of human microbiota in a rigorously controlled manner. 
A typical isolator holds up to ~12 cages. To prevent contamination, only one combination of 
microbiota can be used per isolator and regular microbiology testing is necessary (e.g., fecal 
samples and swabs analyzed by Gram staining, PCR, etc.).
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Figure 4. 
Commensal/symbiotic microbiota protect against cancer by multiple mechanisms. 
Schematic of intestine showing 3 compartments: top, the lumen containing microbiota 
(gray); middle, a single layer of epithelial cells; bottom, an underlying lamina propria 
containing immune cells. Commensal/symbiotic bacteria can prevent cancer indirectly by 
outcompeting cancer-causing pathogens and more directly by metabolizing dietary factors 
into bioactive food components (circles). The latter can have cell autonomous effects within 
the cell-of-origin (intestinal epithelial cell, left arrow) and tumor or non-cell autonomous 
effects by preventing immune cell activation and inflammation, which can occur directly 
(middle arrow) or by maintaining the barrier function of the epithelium (right arrow).
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Figure 5. 
Dietary fiber protects against colorectal cancer in a microbiota- and butyrate-dependent 
manner in a gnotobiotic mouse model. Mice were colonized with several bacteria that either 
excluded or included a butyrate producer, Butyrivibrio fibrisolvens, as indicated at the top. 
A wild-type and mutant strain of B. fibrisolvens utilized in separate gnotobiotic isolators 
(depicted by boxes around each group of mice). In each isolator, the mice received control 
or high-fiber diets (6% fructo-oligosaccharides/inulin but otherwise identical to the control 
diet) except for a butyrate-fortified diet in the isolator at the far right. Arrows at the bottom 
indicate relative levels of luminal butyrate along with global histone acetylation levels and 
tumor burden following AOM treatment. Butyrate production was attenuated, but not 
completely abolished, in the mutant strain when provided a high-fiber diet as denoted by one 
upward butyrate arrow instead of a downward arrow or two upward arrows. The ovals 
highlight experimental conditions that yield a lower tumor burden, and this correlates with 
higher butyrate levels and histone acetylation levels.
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Figure 6. 
Mechanism of butyrate-mediated tumor suppression. In normal colonocytes (left), butyrate 
is utilized as the primary energy source and metabolized in the mitochondria so relatively 
little accumulates inside of the cell. In cancerous colonocytes (right), glucose is the primary 
energy source due to the Warburg effect. Butyrate is still transported into the cell via 
monocarboxylate transporters but is not metabolized in the mitochondria, which allows it to 
accumulate in the nucleus and function as an HDAC inhibitor to epigenetically regulate 
genes involved in cell proliferation and apoptosis.
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Figure 7. 
Cancer cells undergo the Warburg effect to support their rapid proliferation. Normal cells 
that are not transformed usually metabolize glucose by undergoing oxidative metabolism in 
the mitochondria (TCA cycle and OXPHOS), which yields 36 ATPs per glucose molecule. 
In contrast, cancer cells undergo aerobic glycolysis and generate lactate as an end product, 
which yields 4 ATPs per glucose molecule (only 2 ATPs if oxygen is limited in a hypoxic 
environment). The cancer cell makes up for this inefficient energy production mechanism by 
upregulating glucose transporters (GLUTs) and increasing glucose uptake, and this is the 
basis for tumor imaging in the clinic (via FDG-PET). Because glucose is not metabolized 
completely to CO2, the pentose phosphate pathway and salvage pathways scavenge carbons 
and nitrogens from glycolytic intermediates to replenish the pools of dNTPs, amino acids 
(AAs), and fatty acids (FAs). This serves a conduit for biosynthetic pathways to replicate 
DNA in the nucleus, all of the proteins in the proteome, and lipids. The rationale behind this 
strategy is that acquiring the raw materials to double cellular biomass is a more important 
challenge for rapidly dividing cancer cells than generating sufficient ATP levels.
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Figure 8. 
Chemoprevention versus chemotherapy. Probiotics/prebiotics can increase levels of 
butyrate, which is an endogenous HDAC inhibitor that does not have adverse effects 
associated with synthetic HDAC inhibitors used in chemotherapy because its bioavailability 
is primarily restricted to the colon and it targets tumor cells because of the Warburg effect. 
See text for further explanation.
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Table 1
Bacterial metabolites derived from food components reported to have chemopreventive effects
Whole food Dietary
component
Bacterial
metabolite
Potential mechanism(s) of
chemoprevention
Fruits, vegetables, grains Fiber Butyrate - Energy source for colonocytes
- HDAC inhibitor (cell cycle, apoptosis)
- Ligand for GPRs
- Anti-inflammatory effects
Berries, walnuts, pomegranates Ellagic acid Urolithins - Alters estrogenic activities
- Inhibits COX-2 and inflammation
Soy-based products Daidzein Equol - Binds to estrogen receptors (ER) and regulates 
their function
- Antioxidant
Cruciferous vegetables (e.g., 
broccoli)
Glucosinolates Isothiocyanates - Bacterial thioglucosidases convert 
glucosinolates to isothiocyanates in cooked 
vegetables
- Inactivate carcinogens
- HDAC inhibitor (cell cycle, apoptosis)
- Anti-inflammatory effects
Vegetable oils Linoleic acid Conjugated linoleic acid - Ratio of omega-3 and omega-6 PUFAs
- Anti-inflammatory effects
- Inhibition of angiogenesis to minimize tumor 
vascularization
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